The Protocol Specific Research Support (PSRS) provides funding for innovative, short term, feasibility and phase I clinical trials originating from scientific investigators within KCI. The primary objective is to foster investigator-initiated trials that bring new results from the basic science laboratories to KCI's clinics. PSRS provides funding to encourage expansion of the number of investigator-initiated protocols and the development of innovative trials that may have insufficient preliminary data to be competifive for peer reviewed funding. The Clinical Research Coordinator (CRC) and Business Analyst funded by PSRS provide data management and study coordination in support of high priority, innovative, feasibility and phase I invesfigator-inifiated clinical research protocols. The services provided by the CRC are in accordance with the services of the Clinical Trials Office Core (Secfion 9.1.10). The Business Analyst creates protocol specific calendars and electronic case report forms (eCRFs) within OnCore?. The information captured in the eCRF is used by the Biostatistics Core for protocol data analysis.

Public Health Relevance

The purpose of PSRS is to provide data management support for innovafive, short term, feasibility and phase I clinical trials originating from scientific invesfigators within KCI. The primary objecfive is to foster investigator-initiated trials that bring new results from the basic science laboratories to the KCI clinics.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wayne State University
United States
Zip Code
Ratanatharathorn, V; Deol, A; Ayash, L et al. (2015) Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. Bone Marrow Transplant 50:106-12
Bollig-Fischer, Aliccia; Chen, Wei; Gadgeel, Shirish M et al. (2015) Racial diversity of actionable mutations in non-small cell lung cancer. J Thorac Oncol 10:250-5
Motzer, Robert J; Rini, Brian I; McDermott, David F et al. (2015) Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 33:1430-7
Wijesinghe, Priyanga; Bepler, Gerold; Bollig-Fischer, Aliccia (2015) A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer. J Thorac Oncol 10:381-6
Koo, Imhoi; Yao, Sen; Zhang, Xiang et al. (2014) Comparative analysis of false discovery rate methods in constructing metabolic association networks. J Bioinform Comput Biol 12:1450018
Koo, Imhoi; Wei, Xiaoli; Shi, Xue et al. (2014) Constructing Metabolic Association Networks Using High-dimensional Mass Spectrometry Data. Chemometr Intell Lab Syst 138:193-202
Heng, D Y C; Choueiri, T K; Rini, B I et al. (2014) Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 25:149-54
Szalai, Gabor; Xu, Yi; Romero, Roberto et al. (2014) In vivo experiments reveal the good, the bad and the ugly faces of sFlt-1 in pregnancy. PLoS One 9:e110867
Bengsch, F; Buck, A; Gunther, S C et al. (2014) Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncogene 33:4474-84
Speyer, Cecilia L; Hachem, Ali H; Assi, Ali A et al. (2014) Metabotropic glutamate receptor-1 as a novel target for the antiangiogenic treatment of breast cancer. PLoS One 9:e88830

Showing the most recent 10 out of 321 publications